Price history
¥613Latest+1.0%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview
A summary lands here once the filings have been read.
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
News
Key numbersShowing 8 of 16
PBR
4.1How many times the company's net assets? Around 1x is generally considered a benchmark.ROE
-50.4%Earning power. A figure above 10% is generally considered good.Dividend yield
0.0%The annual dividend as a percentage of the share price.Market capitalization
¥5.1bnShare price × number of shares. The value of the entire company.Equity ratio
60.9%The proportion of assets funded by money that does not have to be repaid.Operating margin
-196.0%The percentage of revenue remaining from the company’s core business.Revenue growth (3 years)
85.0%The average annual growth in sales over the past three years.PSR
15.91The number of times sales are valued. Used to assess companies that are not profitable.What to watch next
The next update on Phase III development and preparations for regulatory filing for KP-100IT (acute spinal cord injury), including discussions with PMDA and greater clarity on the filing stage
Impact HighLikelihood Medium
Progress in the Phase III trial for KP-100LI (vocal fold scarring), including expansion of trial sites and milestones in enrollment and primary assessments
Impact MediumLikelihood Medium
Continuation or revision of the terms of the License and Supply Agreement with Claris Biotherapeutics, including active pharmaceutical ingredient supply and royalties, to confirm the resilience of revenue
Impact MediumLikelihood Medium
Continuity and supply stability of the master cell bank license (derived from Neurogen) and the external CDMO structure involving 2 companies for active pharmaceutical ingredients and drug products, including whether manufacturing risks materialize or are avoided
Impact HighLikelihood Low
Whether additional financing through stock acquisition rights is conducted and a reassessment of the scale of dilution
Impact MediumLikelihood Medium
What to watch next
Who owns itTop holders total 25.2%
Listed holders 25.2%Everyone else 74.8%
日本全薬工業株式会社7.14%
STATE STREET BANK AND TRUST COMPANY 510643 (Standing proxy: Mizuho Bank, Settlement Services Department)3.52%
CYBERDYNE, INC.2.85%
山田 哲夫2.52%
Nomura Securities Co., Ltd.1.74%
高山 二郎1.71%
上田八木短資株式会社1.59%
丸石製薬株式会社1.42%
2 other listed holders2.75%
| Holder | Ownership (%) |
|---|---|
| 日本全薬工業株式会社 | 7.14 |
| STATE STREET BANK AND TRUST COMPANY 510643 (Standing proxy: Mizuho Bank, Settlement Services Department) | 3.52 |
| CYBERDYNE, INC. | 2.85 |
| 山田 哲夫 | 2.52 |
| Nomura Securities Co., Ltd. | 1.74 |
| 高山 二郎 | 1.71 |
| 上田八木短資株式会社 | 1.59 |
| 丸石製薬株式会社 | 1.42 |
| 2 other listed holders | 2.75 |
This company's documents
Timely disclosures
- 2026-10-19Notice of Earnings Briefing and Live Streaming (Zoom Webinar)
- 2026-10-19Notice of the U.S. FDA IND becoming effective for oremepermin alfa for acute spinal cord injury
- 2026-10-13Business partner Claris announces favorable clinical proof-of-concept data for CSB-001 in LSCD
- 2026-10-07Notice of exhibition at the "Japan Healthcare Venture Summit 2026"
- 2026-10-05Announcement of presentation by alliance partner Claris Biotherapeutics at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
- 2026-09-28Partner Claris Biotherapeutics Relocates Headquarters to the San Francisco Bay Area — Accelerating Clinical Development and Strengthening Its Foundation for Growth
- 2026-09-24Notice of IND (Investigational New Drug) Application to the U.S. FDA for oremepermin alfa for Acute Spinal Cord Injury
- 2026-09-16Notice regarding the execution of an agreement concerning the exclusive distribution license in Japan for a treatment for vocal cord scarring
44 more
- 2026-09-16Notice Regarding Revisions to Earnings Forecasts for the Fiscal Year Ending September 2026
- 2026-09-16Notice Concerning the Introduction of an Executive Officer System
- 2026-09-09Notice of Update to the Financial Results Report for the Third Quarter of the Fiscal Year Ending September 2026
- 2026-09-04Notice of the Start of Joint Research with Yokohama City University on a Study Evaluating the Efficacy of Hepatocyte Growth Factor (HGF) for Peripheral Neuropathy
- 2026-09-01Research project with Gifu University School of Medicine on the application of HGF to idiopathic osteonecrosis of the femoral head selected for an AMED program
- 2026-08-29Notice of Resolutions Adopted at the Extraordinary General Meeting of Shareholders
- 2026-08-27Notice Regarding the Large-Scale Exercise of the 16th Series of Stock Acquisition Rights Issued through a Third-Party Allotment (with Exercise Price Adjustment Clause)
- 2026-08-27Notice Regarding Completion of Exercise of the 16th Series of Stock Acquisition Rights Issued through a Third-Party Allotment (with Exercise Price Adjustment Clause) and Monthly Exercise Status
- 2026-08-20Notice of the publication of a Logmi Finance transcript article for the video "2026 Fiscal Year Ending September: Third-Quarter Financial Results Briefing"
- 2026-08-10Notice of the Posting of an Explanatory Video on the Financial Results for the Third Quarter of the Fiscal Year Ending September 2026
- 2026-08-10Third-Quarter Financial Results for the Fiscal Year Ending September 2026 (Financial Results Presentation)
- 2026-08-10Financial Results for the Third Quarter of the Fiscal Year Ending September 2026 (Japanese GAAP) (Non-consolidated)
- 2026-08-06Notice of Convocation of an Extraordinary General Meeting of Shareholders
- 2026-08-03Notice Regarding the Monthly Exercise Status of the 16th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued Through a Third-Party Allotment
- 2026-07-29Notice Regarding Series B Financing by Partner Claris Biotherapeutics, Future Development Plans and Strengthening of Management Structure
- 2026-07-28Notice of a Published Paper on the Results of a Phase III Clinical Trial of HGF (Hepatocyte Growth Factor) in Acute Spinal Cord Injury
- 2026-07-27Kinjo Kazuki (金城一貴), our Head of Corporate Strategy Office, will speak at the Regenerative Medicine Leading Scientist Session Vol. 2.
- 2026-07-24Notice of Public Disclosure of Registration Information for the Additional Phase III Clinical Trial of HGF (Hepatocyte Growth Factor) in Acute Spinal Cord Injury
- 2026-07-23Notice of the publication in an international academic journal of a paper on traumatic cervical spinal cord injury by the North American Spinal Cord Injury Consortium, which we support
- 2026-07-16Participation in the international spinal cord injury consortium “SCI PFDD” — advancing patient-centered global drug development for spinal cord injury
- 2026-07-15Basic Agreement on the Exclusive Marketing in Japan of a Drug for Treating Vocal Fold Scarring
- 2026-07-15Entered into a basic agreement with Maruishi Pharmaceutical Co., Ltd. for the exclusive distribution in Japan of a drug for treating vocal cord scarring
- 2026-07-15Notice Regarding a Reduction in the Amounts of Capital and Capital Reserve and the Disposal of Surplus
- 2026-07-07Responses to Questions from Individual Investors
- 2026-07-03Completion of PMDA Review of the Clinical Trial Notification for the Additional Phase III Trial of HGF (Hepatocyte Growth Factor) in Acute Spinal Cord Injury
- 2026-07-01Notice Regarding the Monthly Exercise Status of the 16th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued Through a Third-Party Allotment
- 2026-06-29(Correction) Partial Correction to the "Notice Concerning the Issuance of Stock Options (Share Acquisition Rights)"
- 2026-06-26Notice Regarding the Finalization of the Terms of Stock Options (Share Acquisition Rights)
- 2026-06-19Submission of a clinical trial notification for an additional Phase III study of HGF (hepatocyte growth factor) in acute spinal cord injury
- 2026-06-15Notice of the Start of Joint Research with Keio University on Acute-Phase Protein Biomarkers for Predicting Natural Recovery and Evaluating Treatment Efficacy After Spinal Cord Injury
- 2026-06-10Notice Concerning the Issuance of Stock Options (Share Acquisition Rights)
- 2026-06-10Notice Regarding the Setting of a Record Date for Convening an Extraordinary General Meeting of Shareholders
- 2026-06-08Notice of Update to the Financial Results Report for the Second Quarter of the Fiscal Year Ending September 2026
- 2026-06-01Notice Regarding the Monthly Exercise Status of the 16th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued Through a Third-Party Allotment
- 2026-05-21Our president, Adachi Kiichi (安達喜一), has been appointed chairman of the Japan Biotech Council
- 2026-05-20Notice of Publication of a Logmi Finance Transcript Article on the Video of the “Second-Quarter Financial Results Briefing for the Fiscal Year Ending September 2026”
- 2026-05-20Notice Regarding the Large-Scale Exercise of the 16th Series of Stock Acquisition Rights Issued through a Third-Party Allotment (with Exercise Price Adjustment Clause)
- 2026-05-20Notice Regarding the Presentation of Clinical Data Analysis Results for HGF at the CSRS-Europe Annual Meeting Hosted by the European Cervical Spine Research Society
- 2026-05-18Q&A from the Results Briefing for the Second Quarter of the Fiscal Year Ending September 2026
- 2026-05-14Materials for the Second-Quarter Financial Results Briefing for the Fiscal Year Ending September 2026
- 2026-05-14Notice Regarding the Presentation of an Analysis of Clinical Data on HGF at the Annual Meeting of the Japanese Orthopaedic Association
- 2026-05-11Summary of Financial Results for the Second Quarter of the Fiscal Year Ending September 2026 [Japanese GAAP] (Non-consolidated)
- 2026-05-08Notice Regarding Certification as an Osaka City Leading Company for Women's Advancement (Three-Star Certification)
- 2026-05-07Notice Regarding a Presentation on Research into the Application of HGF to Idiopathic Pulmonary Fibrosis at the ATS International Conference Hosted by the American Thoracic Society
Threads
- 2026-10-19Transition from a drug-discovery venture to a biopharmaceutical company
- 2026-10-07Open Innovation for New Research Themes Using HGF Protein
- 2026-10-05Expanding HGF Indications to Other Diseases by Leveraging Its Mechanisms of Action
- 2026-09-24Monetization Through International Sales Expansion and API Supply
- 2026-09-16Hybrid Business Model Combining In-House Development, Commercial Partnerships and API Supply
- 2026-09-16Achieving Proof of Concept Through a Next-Stage Trial for Vocal Fold Scarring
- 2026-09-16Building a Domestic Supply Chain with Maruishi Pharmaceutical and TOHO HOLDINGS CO.,LTD.
- 2026-09-16Monetization Through Upfront Fees, Milestones and Royalties
56 more
- 2026-09-16Governance Focused on Corporate and Shareholder Value, Transparency and Fairness
- 2026-09-16Recurring Losses and Negative Operating Cash Flow Due to R&D Investment Ahead of Commercialization
- 2026-09-16Risk of supply chain delays due to failure to establish sales partnerships and delays in overseas partnerships
- 2026-09-16Meeting continued listing criteria through the launch of 2 products in Japan
- 2026-09-01Developing New Pipeline Candidates and Biologics
- 2026-09-01Joint Research With Universities and Specialist Institutions and Use of Public Funding
- 2026-08-29Covering accumulated losses through reductions in stated capital and capital reserves and increasing flexibility in capital policy
- 2026-08-27Strengthening the Financial Position Through Equity Financings, API Supply and Joint Development
- 2026-08-27Raising Funds Through a Stock Listing and Private Placement
- 2026-08-27Dilution of Share Value from the Exercise of Stock Acquisition Rights
- 2026-08-10Completion of the Phase III Clinical Trial for KP-100IT and Submission of the Application for Marketing Approval
- 2026-08-10Completion of the Phase II ALS Trial and Development of an Approval-Filing Strategy
- 2026-08-10Establishing a Commercial-Scale API Supply System
- 2026-08-10Uncertainty Regarding Clinical Trial Efficacy, Safety and Development Success
- 2026-08-10Liquidity and Additional Funding Risks Before Commercial Launch
- 2026-08-10High Research and Development Expenses and the Risk of Additional Costs
- 2026-07-28Achieving Proof of Concept in Acute Spinal Cord Injury
- 2026-07-23Patient-centered global drug development for spinal cord injury
- 2026-06-26Expanding Human Capital and Establishing Flexible Work and Training Programs
- 2026-05-18Concentration of Management Resources on Recombinant Human HGF Protein
- 2026-05-18Leveraging Orphan Drug Designation for Acute Spinal Cord Injury
- 2026-05-18Pre-Application Consultation for Orphan Drug Designation for Vocal Fold Scarring
- 2026-05-14Constraints on Development and Administration From a Small Organization and Recruitment Challenges
- 2026-05-01Supporting Patients and Contributing to Society Through Treatments for Intractable Diseases
- 2026-04-01Building a Global Intellectual Property Base Through European Patent Registration for the HGF Formulation
- 2025-12-19Uncertainty Regarding Marketing Business Licenses and Marketing Approval
- 2025-05-12Near-Term No-Dividend Policy to Prioritize Research and Development
- 2025-05-12Designation of the International Nonproprietary Name “Oremepermin Alfa” for KP-100
- 2025-05-12Decline in Selling Prices Due to Drug Price Revisions and Healthcare System Reform
- 2025-05-12Pharmaceutical companies’ M&A activity, narrowing of focus areas, and in-licensing of development-stage products against a backdrop of rising new drug development costs
- 2025-05-12A shift in drug development from blockbuster drugs to medicines for specific patient populations and the role of drug discovery ventures
- 2025-05-12Government Support for Biotech Startups and the Environment for Using Conditional Early Approval and Other Programs
- 2025-05-12Executive Incentives and Alignment with Shareholder Value Through a Restricted Stock Compensation Plan
- 2024-12-23Clinical Development Delays and the Impact of COVID-19
- 2024-12-23Dependence on Sales, Wholesale and API Supply Partners
- 2024-12-23Share Price Declines Resulting from Share Sales by Venture Capital Funds and Others
- 2024-12-23Mitigating the Impact of COVID-19 Through Remote Work and Staggered Hours
- 2024-05-13Receipt of an Academic Award for the Phase I/II Acute Spinal Cord Injury Trial
- 2023-12-25Contributing to the Resolution of Social Issues and Sustainability Through the Core Business
- 2023-12-25No Quantitative Indicators or Targets Set for Human Capital; Consideration of Whether to Establish Them
- 2022-12-26Commercialization through In-House Development and Regulatory Applications
- 2022-12-26Policy of Using Development Progress as a Management Target
- 2022-12-26Resumption of Acute Kidney Injury Development After Securing Funding
- 2022-12-26Outsourced Manufacturing Through Contract Manufacturing Organizations
- 2022-12-26Strengthening audit functions through the transition to a company with an Audit & Supervisory Board
- 2022-12-26Controls Through the Compliance and Risk Management Committee
- 2022-12-26Uncertainty in Future Revenue Projections
- 2022-12-26Impact of Potential Competitor Development on Profitability
- 2022-12-26Risk of Disputes Involving Third-Party Intellectual Property Rights
- 2022-12-26Dependence on a License to Use the Master Cell Bank
- 2022-12-26Dependence on Specialty Raw Materials and a Limited Number of Suppliers
- 2022-12-26Risks Relating to the Continuity and Quality Control of Outsourced Manufacturing
- 2022-12-26Dependence on the Representative Director and Certain Employees
- 2022-12-26Loss of Competitive Advantage from the Leakage of Manufacturing Technology and Know-How
- 2022-12-26Protecting Manufacturing Methods as Confidential Know-How
- 2022-12-26Liability for Damages from Serious Adverse Reactions During Clinical Trials and After Commercialization